| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/03/2006 | US6982248 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| 01/03/2006 | US6982247 isolated peptide or protein of given sequence derived from the mucus of the foot sole of Archachatina marginata, a West-African snail; use against viral, bacterial or fungal infections |
| 01/03/2006 | US6982246 oligopeptides comprising a sequence associated with HLA-B alpha 1 domain, but comprising a tyrosine-tyrosine-tryptophan triad; preventing organ transplant rejection; side effect reduction so the patient can still fight infections |
| 01/03/2006 | US6982160 Immunogenic compositions that include SIRS virus |
| 01/03/2006 | US6982156 comprises antibodies against Smallpox Inhibitor of Complement Enzyme (SPICE) or Vaccinia Virus Complement Control Protein (VCP); dna vaccines |
| 01/03/2006 | US6982154 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| 01/03/2006 | US6982153 DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides |
| 01/03/2006 | US6982149 Fiber array and methods for using and making same |
| 01/03/2006 | US6982089 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 01/03/2006 | US6982085 Induce antibody response; drugs, medical diagnosis |
| 01/03/2006 | US6982084 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 01/03/2006 | US6982083 Starch granules containing a recombinant polypeptide of interest, method for obtaining them, and their uses |
| 01/03/2006 | US6982081 Measuring blood concentration of oligoadenylate synthetase; monitoring disease |
| 01/03/2006 | US6982080 Hydroxyethyl starch—containing polypeptide compositions |
| 01/03/2006 | US6982075 Administering a pulmonary surfactant preparation, including a phosphatide and/or a surfactant protein to artificially respirate a patient suffering from a toxic oxygen concentration; side effect reduction |
| 01/03/2006 | CA2316834C Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
| 01/03/2006 | CA2235747C Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis |
| 01/03/2006 | CA2187449C Anti-cancer compounds containing cyclopentaquinazoline ring |
| 01/03/2006 | CA2176117C Generation of high titers of recombinant aav vectors |
| 01/03/2006 | CA2158937C Recombinant alphavirus vectors |
| 01/03/2006 | CA2138974C Dermatological agent for aiding oxygen transport in the skin |
| 01/03/2006 | CA2070979C Sequence specific dna binding by p53 |
| 01/01/2006 | CA2502425A1 Allergen from house-dust mites |
| 12/29/2005 | WO2005124346A1 4-1bb receptors are expressed on regulatory t-cells |
| 12/29/2005 | WO2005124342A2 Methods and means for treatment of osteoarthritis |
| 12/29/2005 | WO2005124230A1 Photochromic material comprising a proteorhodopsin apoprotein and retinal analog |
| 12/29/2005 | WO2005123958A2 Cd7 as biomarker and therapeutic target for psoriasis |
| 12/29/2005 | WO2005123935A1 Method of producing therapeutically useful product and system |
| 12/29/2005 | WO2005123931A1 System and method for electroporating a sample |
| 12/29/2005 | WO2005123916A2 Glycosylation-disrupted factor vii variants |
| 12/29/2005 | WO2005123771A2 Oligomeric peptides and their use for the treatment of hiv infections |
| 12/29/2005 | WO2005123770A1 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| 12/29/2005 | WO2005123769A1 Hla-a2-binding protein originating in prostate-related antigen |
| 12/29/2005 | WO2005123767A1 Peptide-based compounds |
| 12/29/2005 | WO2005123761A1 GnRH ANALOGS BACKBONE CYCLIZED THROUGH METAL COMPLEXATION |
| 12/29/2005 | WO2005123132A2 Use of liver-selective glucokinase activators |
| 12/29/2005 | WO2005123128A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | WO2005123119A2 Administration of neutral endopeptidase to treat inflammatory bowel disease |
| 12/29/2005 | WO2005123118A1 Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) |
| 12/29/2005 | WO2005123117A1 Treatment of non alcoholic steatotic hepatitis (nash) |
| 12/29/2005 | WO2005123116A2 Compositions and methods for treating or preventing oxalate-related disease |
| 12/29/2005 | WO2005123115A1 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants |
| 12/29/2005 | WO2005123114A2 Silk-based drug delivery system |
| 12/29/2005 | WO2005123113A2 Interferon compositions and methods of use thereof |
| 12/29/2005 | WO2005123112A2 Method of enhancing the immune response to a vaccine |
| 12/29/2005 | WO2005123111A2 Maxs as modifiers of the axin pathway and methods of use |
| 12/29/2005 | WO2005123110A2 Compositions comprising various proteorhodopsins and/or bacteriorhodopsins and use thereof |
| 12/29/2005 | WO2005123109A2 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| 12/29/2005 | WO2005123107A2 Immune response suppressor and treatment of multiple sclerosis |
| 12/29/2005 | WO2005123106A1 Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester to treat sunburn and other burns |
| 12/29/2005 | WO2005123105A1 Phototoxic compounds |
| 12/29/2005 | WO2005123104A2 Use of vegf inhibitors for the treatment of human cancer |
| 12/29/2005 | WO2005123103A1 Topical compositions and methods for epithelial-related conditions |
| 12/29/2005 | WO2005123102A1 Control of canine voluntary food intake |
| 12/29/2005 | WO2005123059A1 Alpha-ketoglutatic acid or derivatives thereof for the treatment of osteoporosis and related diseases |
| 12/29/2005 | WO2005123056A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids |
| 12/29/2005 | WO2005107793A3 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| 12/29/2005 | WO2005105995A3 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/29/2005 | WO2005102380A3 Methods of inhibiting inflammation |
| 12/29/2005 | WO2005097174A3 Uses of a combination of ghrelin and somatotropin for the treatment of cachexia |
| 12/29/2005 | WO2005097173A3 Use of ghrelin for the treatment of hyperthyroidism |
| 12/29/2005 | WO2005094423A3 Selective inhibition of proteasomes of tuberculosis and other bacteria |
| 12/29/2005 | WO2005082348A3 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
| 12/29/2005 | WO2005072270A3 Methods and compositons for treating cancer |
| 12/29/2005 | WO2005069888A3 Smac peptidomimetics and the uses thereof |
| 12/29/2005 | WO2005067500A3 Enhancement of immune responses |
| 12/29/2005 | WO2005065121A3 Methods and compositions for the production of monoclonal antibodies |
| 12/29/2005 | WO2005058233A3 Methods for treatment of acute pancreatitis |
| 12/29/2005 | WO2005056578A3 High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers |
| 12/29/2005 | WO2005051975A3 Methods for obtaining molecules with reduced immunogenicity |
| 12/29/2005 | WO2005048952A3 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 12/29/2005 | WO2005046587A3 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| 12/29/2005 | WO2005045037B1 RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/29/2005 | WO2005044142A3 Intravascular devices and fibrosis-inducing agents |
| 12/29/2005 | WO2005042698A3 T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same |
| 12/29/2005 | WO2005037990A3 Use of parp inhibitors for prevention and treatment of diabetic and insulin resistance complications |
| 12/29/2005 | WO2005037236A3 Novel heat shock protein 20-related polypeptides and uses therefor |
| 12/29/2005 | WO2005035733A3 Modified whole cell, cell extract and omv-based vaccines |
| 12/29/2005 | WO2005034881A3 Methods and compositions for treating conditions involving abnormal angiogenesis |
| 12/29/2005 | WO2005028650A3 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/29/2005 | WO2005023996A3 METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-β PROTEINS (TGF-βs) IN CELLS |
| 12/29/2005 | WO2005016273A3 Infection prophylaxis using immune response modifier compounds |
| 12/29/2005 | WO2004100872A3 Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
| 12/29/2005 | WO2004099372A3 Anti-scarring ribozymes and methods |
| 12/29/2005 | WO2004094599A3 Disease prevention and vaccination following thymic reactivation |
| 12/29/2005 | WO2004085998A3 Biomimetic hierarchies using functionalized nanoparticles as building blocks |
| 12/29/2005 | WO2004085665A3 Nucleic acid ligand to b. anthracis protective antigen |
| 12/29/2005 | WO2004074437A3 Compositions and methods for cancer immunotherapy |
| 12/29/2005 | WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 12/29/2005 | WO2004053099A3 A method for treatment of drug addiction and for screening of pharmaceutical agents therefor |
| 12/29/2005 | WO2004046341A3 Modulation of kiaa0415 expression |
| 12/29/2005 | WO2004046327A3 Inhibitory oliogonucleotides targeted to bcl-2 |
| 12/29/2005 | WO2004045544A8 Autocrine growth factor receptor antibodies and methods |
| 12/29/2005 | WO2004035758A3 Rna-based inhibitory oligonucleotides |
| 12/29/2005 | WO2004021861A3 Targeted release |
| 12/29/2005 | WO2004013280A3 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
| 12/29/2005 | WO2004004661A3 Boroproline compound combination therapy |
| 12/29/2005 | WO2003071933A3 Novel compositions and methods for cancer |
| 12/29/2005 | WO2003068155A3 Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy |
| 12/29/2005 | WO2003033671A3 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |